CClinicalTrials.gg
Status unknownNCT06229756Updated Jan 29, 2024

Clinical Results of Asqelio™ EDOF Toric Soft Hydrophobic Intraocular Lens After Cataract Surgery

An observational study in Cataract, sponsored by AST Products, Inc.. Status unknown at 1 site in Spain. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by AST Products, Inc. · Observational

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
50 Years and older
Sex
All
01

Study summary

The goal of this observational study is to assess the clinical outcomes of binocular implantation of Asqelio EDOF Toric IOLs in healthy cataract patients. The main questions it aims to answer are:

  • What is the visual performance at different distances 3 months after implantation of Asqelio EDOF Toric in both eyes?
  • What is the amount of residual refractive error following the implantation?
  • What is the contrast sensitivity of patients 3 months after implantation of Asqelio EDOF Toric in both eyes?
  • What is the optical quality of the eye implanted with Asqelio EDOF Toric IOL?
  • What is the incidence and severity of visual symptoms after implantation of Asqelio EDOF Toric?
  • What is the level of patient satisfaction after implantation of Asqelio EDOF Toric?

For this purpose, participants will be submitted to a comprehensive visual and refractive assessment, following common clinical practice, 3 months after binocular implantation of Asqelio EDOF Toric IOLs, and asked to complete visual symptoms and patient satisfaction questionnaires.

02

Conditions studied

03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy subjects submitted to bilateral cataract surgery with implantation of extended depth of focus IOLs according to common clinical practice

Inclusion criteria

  • Patients 50 years old or more submitted to bilateral cataract surgery and implanted with Asqelio EDOF toric IOL, with cylinder value of 0.0 D.
  • Patients signing informed consent
  • Transparent media except for the cataracts
  • Potential postoperatoria visual acuity of 20/25 or better

Exclusion criteria

Exclusion Criteria:

  • Preoperative corneal astigmatism greater than 1.00D
  • Patients who do not provide informed consent
  • Patients who do not understand the study procedure
  • Previous corneal surgery or trauma
  • Irregular cornea (e.g. keratoconus)
  • Choroidal hemorrhage
  • Microphtalmos
  • Severe corneal dystrophy
  • Uncontrolled or medically controlled glaucoma
  • Clinically significant macular changes
  • Concomitant severe eye disease
  • Non-age-related cataract
  • Severe optic nerve atrophy
  • Diabetic retinopathy
  • Proliferative diabetic retinopathy
  • Amblyopia
  • Extremely shallow anterior camera
  • Severe chronic uveítis
  • Pregnant or nursing
  • Rubella
  • Mature/dense cataract that makes it difficult to examine the fundus preoperatively.
  • Previous retinal detachment
  • Concurrent participation in other research with drugs or clinical devices
  • Expect to require another eye surgery during the study period
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • EDOF Toric

    Patient submitted to bilateral implantation of Asqelio EDOF Toric IOL

05

What researchers measure

Primary outcomes

  1. Uncorrected Monocular Visual acuity for distance

    Visual acuity without additional correction determined at a distance of 4 m in LogMAR units

    Time frame: 3 months after implantation

  2. Uncorrected Monocular Visual acuity for intermediate distance

    Visual acuity without additional correction determined at a distance of 67 cm in LogMAR units

    Time frame: 3 months after implantation

  3. Uncorrected Monocular Visual acuity for near distance

    Visual acuity without additional correction determined at a distance of 40 cm in LogMAR units

    Time frame: 3 months after implantation

  4. Corrected Monocular Visual acuity for distance

    Visual acuity with best correction determined at a distance of 4 m in LogMAR units

    Time frame: 3 months after implantation

  5. Corrected Monocular Visual acuity for intermediate distance

    Visual acuity with best correction determined at a distance of 67 cm in LogMAR units

    Time frame: 3 months after implantation

  6. Corrected Monocular Visual acuity for near distance

    Visual acuity with best correction determined at a distance of 40 cm in LogMAR units

    Time frame: 3 months after implantation

  7. Refractive error

    Residual refractive error after implantation obtained by subjective refraction methods

    Time frame: 3 months after implantation

Secondary outcomes

  1. Contrast sensitivity function under photopic conditions

    Contrast sensitivity measured under photopic conditions for spatial frequencies of 3, 6, 12 and 18 cycles per degree using the Clinical Trial Suite in logCS units

    Time frame: 3 months after implantation

  2. Contrast sensitivity function under mesopic conditions

    Contrast sensitivity measured under mesopic conditions for spatial frequencies of 1.5, 3, 6 and 12 cycles per degree using the Clinical Trial Suite in logCS units

    Time frame: 3 months after implantation

  3. Contrast sensitivity function under photopic conditions with glare

    Contrast sensitivity measured under photopic conditions inducing glare, for spatial frequencies of 3, 6, 12 and 18 cycles per degree using the Clinical Trial Suite in logCS units

    Time frame: 3 months after implantation

  4. Contrast sensitivity function under mesopic conditions with glare

    Contrast sensitivity measured under mesopic conditions inducing glare, for spatial frequencies of 1.5, 3, 6 and 12 cycles per degree using the Clinical Trial Suite in logCS units

    Time frame: 3 months after implantation

  5. Binocular defocus curve

    Visual acuity in logMAR units under binocular conditions, determined varying the stimulus mergence using lenses from -4.00D to +2.00D in 0.50D steps and best refractive correction for distance

    Time frame: 3 months after implantation

  6. Aberrometry

    Optical quality measured as Zernike coefficients for total Root Mean Square of Higher order aberrations, and Spherical aberrations, expressed in microns

    Time frame: 3 months after implantation

  7. Light distortion

    Distortion of light as light distortion index, determined by means of the light distortion analyzer

    Time frame: 3 months after implantation

  8. Patient-reported visual symptoms

    Incidence and severity of visual symptoms, determined by means of a visual symptoms questionnaire. Incidence will be scored in a scale from 1 (never) to 4 (always), severity from 1 (none) to 4 (severe), and bothersome rom 1(none) to 4 (a lot)

    Time frame: 3 months after implantation

  9. Patient-reported satisfaction

    Level of satisfaction with vision and difficulty performing daily activities, determined by means of the CATQuest 9SF questionnaire, where items are scored in a scale from 1 (yes, a lot of difficulties) to 4 (no, no difficulties) and a "cannot decide" option. Satisfaction is scored from 1 (very unsatisfied) 4 (very satisfied) and a "cannot decide" option

    Time frame: 3 months after surgery

  10. Incidence of Adverse events

    Percentage of patients presenting adverse events (ocular and non ocular, severe and not severe), including secondary surgical procedures

    Time frame: 3 months after surgery

06

Study locations

1 site
  • OftalVist Alicante
    Alicante, 03015, Spain
07

Registry details

Key details

Study ID
NCT06229756
Lead sponsor
AST Products, Inc.
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Oct 26, 2022
Primary completion
Mar 2024 (estimated)
Completion
Apr 2024 (estimated)
Last update
Jan 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion